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Abstract: Background: The development of multifunctional wound dressings with the ability
to control hemostasis, limit infection and promote rapid wound healing and constructive tissue
remodeling has been a challenge for many years. In view of these challenges, a hybrid scaffold
platform was developed that combined two different extracellular matrices (ECM): ECM from
decellularized mammalian tissue and ECM (chitosan) from crustaceans. Both types of ECM have
well established clinical benefits that support and promote wound healing and control hemostasis.
This scaffold platform could also be augmented with antibiotics to provide bactericidal activity
directly to the wound site. Methods: Four different scaffold formulations were developed containing
chitosan supplemented with either 20% or 50% urinary bladder matrix (UBM) hydrogel or 1% (w/v)
or 10% (w/v) UBM–ECM particulates. 100% chitosan scaffolds were used as controls. The scaffolds
were augmented with either minocycline or rifampicin. Escherichia Coli and Staphylococcus Aureus
were used to assesses antimicrobial efficacy and duration of activity, while neutral red uptake assays
were performed to establish direct and indirect cytotoxicity. Results: Results showed that scaffold
handling properties, scaffold integrity over time and the efficacy and release rate of loaded antibiotics
could be modified by altering scaffold composition. Moreover, antibiotics were easily released
from the scaffold and could remain effective for up to 24 h by modifying the scaffold composition.
Variable results with cytotoxicity testing show that further work is required to optimize the scaffold
formulations but these proof of principle experiments suggest that these scaffolds have potential as
bioactive wound dressings.
Keywords: chitosan; extracellular matrix; antimicrobial; biocompatible; scaffold; wound healing;
regenerative medicine
1. Introduction
At its simplest, a superficial wound can be described as damage to the skin due to burn, trauma or
incision. However, this description fails to appreciate the complex nature of the wound environment
and the unique problems that define the severity of the wound as it relates to variables such as
trauma type, location and size. Severe wounds can lead to death as a result of infection or blood
loss and frequently require specialist wound dressings and intensive care. However, while there
is a high demand for wound dressings to enhance hemostasis, accelerate tissue repair and combat
infection, advances in wound dressing technology are lacking due in part to the intrinsic complexity
of the wound healing process. Ideal wound dressings should conform to the wound, help maintain
a moist environment while assisting with the removal of wound exudates and facilitate the wound
healing process. Additionally, attributes such as control of infection, hemostasis and promotion
of constructive tissue remodeling would be desirable features. Choice of wound dressing ranges
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from the relatively simple, such as paraffin-gauze, to complex hydrogels and colloids that may or
may not contain bioactive factors to promote angiogenesis or re-epithelialization. More recently, the
development of biologic dressings for wound repair has resulted in dressing materials that attempt to
restore the wound microenvironment by providing either bioactive factors, extracellular matrix (ECM)
components or both to stimulate granulation tissue formation, angiogenesis and re-epithelialization.
Two such materials are chitosan and ECM derived from decellularized tissues.
Chitosan is a β-1,4-linked polymer of glucosamine (2-amino-2-deoxy-β-d-glucose) and lesser
amounts of N-acetylglucosamine. It is a derivative of chitin (poly-N-acetylglucosamine), which is the
second most abundant biopolymer after cellulose [1]. The structural characteristics of chitosan mimic
glycosaminoglycan components of the extracellular matrix, while the biocompatibility, biodegradability,
antibacterial [2,3], antioxidant activities and mucoadhesive properties impart versatility. Various
kinds of modification of chitosan have been investigated in recent years using acylation, alkylation,
carboxymethylation and quaternization [4]. Recently, the antibacterial and antifungal activities of
chitosan have been followed with great interest [2,5–7]. Furthermore, incorporation of antibacterial
agents into the chitosan backbone offers excellent antibacterial properties [3,8,9]. Chitosan also has a
strong affinity for binding with red blood cells and blood components allowing chitosan materials to
rapidly clot blood [10–12]. Chitosan-derived materials have recently gained regulatory approval in the
USA for use in bandages and other hemostatic materials [13,14]. In addition, chitosan is known to
modulate the functions of inflammatory cells to promote granulation tissue formation [15–17].
ECM scaffolds derived from decellularized tissues represent the secreted products of resident
cells within each tissue and organ and include structural components such as collagen, laminin and
hyaluronan as well as secreted growth factors, nanovesicles and other signaling molecules. These
molecular components are arranged in tissue specific patterns which are determined by the physiologic
and biomechanical requirements of each tissue [18]. The biologic properties of the matrix are only
partially understood, but they are known to affect the interaction with resident cells and infiltrating cells.
ECM scaffolds modulate cell behavior including alteration of macrophage phenotype, proliferation,
mobilization, and differentiation of stem and progenitor cells, and regulation of angiogenesis, among
others [19–22]. Moreover, the degradation of these scaffolds releases embedded nanovesicles and
cryptic peptide molecules, which play a key role in the biological activity of these materials [23,24]
including antimicrobial activity.
While both chitosan and ECM scaffolds possess antimicrobial activity, the exact mechanisms of the
antimicrobial actions are still uncertain. Therefore, to maximize the antimicrobial effects combination of
these scaffold materials with an antibiotic would be desirable. For example, it has been proposed that
interaction between acidic, or positively charged chitosan molecules and negatively charged microbial
cell membranes leads to the disruption of microbial membrane, and subsequently the leakage of the
intracellular components [25–27].
The overall goal of this project was to develop a hybrid wound dressing composed of chitosan
and ECM proteins along with an antibiotic that would be an effective hemostatic and antimicrobial
dressing. For the present study the objectives were to perform in vitro testing of (1) the effectiveness
and duration of antimicrobial activity; (2) the direct and indirect cytotoxicity of the antibiotic containing
scaffolds in order to identify formulations for future in vivo testing.
2. Materials and Methods
2.1. Preparation of Chitosan:ECM Scaffolds
Chitosan solutions were prepared by dissolving 2% (w/v) chitosan powder (85% deacetylated,
Sigma Aldrich, St. Louis, MO, USA) in dilute acetic acid (2% v/v) under clean conditions. Endotoxin
content of the prepared chitosan solution was assessed using the Pierce Limulus Amebocyte Lysate
(LAL) Chromogenic Endotoxin Quantitation Kit (ThermoFisher Scientific, Waltham, MA, USA)
following the manufacturers recommended protocol. Endotoxin levels were expressed as EU/mL.
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ECM was prepared from porcine urinary bladders (UBM) as previously described [28,29]. Bladders
were briefly harvested from market-weight pigs immediately after death. Excess connective and
adipose tissues were removed from the serosal surface of the bladder and the apex of the bladder was
removed. The bladder was then split longitudinally from the apical opening to the neck of the bladder,
forming a rectangular sheet. Mechanical delamination was performed to remove the he tunica serosa,
tunica muscularis externa, and tunica submucosa, as well as the majority of the muscularis mucosa.
The remaining tissue consisted of only the basement membrane and tunica propria. Decellularization
and disinfection was completed by washing with 0.1% peracetic acid/4% ethanol solution for 2 h
followed by phosphate-buffered saline solution (PBS) (pH 7.4) and water washes. The decellularized
tissue was then frozen and lyophilized.
Two forms of ECM were then prepared to be combined with the chitosan solution. First, the
lyophilized ECM was comminuted into a powder using a Wiley Mill with a 40-mesh screen. The
resulting powder was added to the chitosan solution at either 1% or 10% (w/v) to form two scaffold
formulations. Second, the comminuted powder was digested with pepsin for form a solubilized
ECM hydrogel as previously described [27]. Briefly, the UBM–ECM powder was solubilized by
partial enzymatic digestion in a 1 mg/mL pepsin (Sigma–Aldrich) solution in 0.01 N HCl for 48 h
at a concentration of 10 mg ECM/mL solution (dry wt/vol). To prepare chitosan:ECM scaffolds, the
solubilized ECM was brought to physiologic pH by adding 1/10 the volume of 0.1 N NaOH, the
solution was combined with the chitosan solution at either 80:20 or 50:50 ratios of chitosan to ECM. The
resulting slurries of either chitosan and ECM powder or chitosan:ECM gel were poured into 60 mm
petri dishes (approx. 5 mL per dish) and then frozen and lyophilized forming a sponge like scaffold.
Scaffolds consisting of 100% chitosan a were also prepared in a similar way for comparison control.
Scaffolds consisting of 100% ECM hydrogel were not used as the lyophilized material proved too
friable to make a handleable dressing and would rapidly dissolve when placed in a wet environment.
2.2. Antibiotic Loading of Scaffolds
Chitosan ECM scaffolds were augmented with one of two different antibiotics, rifampicin and
minocycline. These antibiotics were chosen as they are already approved for use in topical dressings.
Since commercially available antibiotic sensitivity testing discs were used for positive controls (30 µg/6
mm diameter disc for minocycline and 5 µg/6 mm diameter disc for rifampicin, (BD BBL Sensi-disc,
Becton Dickinson, Franklin Lakes, NJ, USA)) the antibiotic concentration loaded into the chitosan:ECM
scaffolds was matched and scaled to the 60 mm petri dishes (3 mg per dish for minocycline and 0.5 mg
per dish for rifampicin). The antibiotic powder was added to the chitosan:ECM slurry and stirred
until the antibiotic had completely dissolved. The material was then frozen and lyophilized as for the
nonantibiotic containing scaffolds.
2.3. Direct Antimicrobial Assay
A modification of the Kirby–Bauer antibiotic sensitivity test [30] was used to test the antimicrobial
effectiveness of the different chitosan:ECM scaffold formulations when placed in direct contact with
bacterial. Briefly, clinical isolates of Staphylococcus Aureus (ATCC 29213) and Escherichia Coli (ATCC
25922) were cultured and growth curves of absorbance vs colony forming units (CFU)/mL for both
strains were established. For each bacterial strain, tryptic soy agar plates (100 mm) were prepared and
100 µL of bacterial suspension (1.5 × 108 CFU/mL) was spread across the plate to form a lawn culture.
Using a sterile biopsy punch, 6 mm discs of the chitosan:ECM scaffolds were prepared and placed
onto the inoculated agar plates with sterile forceps. The discs were placed on the plate using a template
to ensure 24 mm center to center spacing between each disc. As a comparison control, antibiotic
sensitivity testing discs for rifampicin and minocycline (BD BBL Sensi-disc) were used. The plates were
then cultured overnight at 37 ◦C and the zone of inhibition around the individual discs was measured
using calipers. Each combination of scaffold was tested in triplicate and the average zone of inhibition
calculated and expressed as a percentage of the control disc.
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2.4. Measurement of Antimicrobial Activity Duration
To test the duration of the antimicrobial activity of the chitosan:ECM scaffolds with and without
antibiotics, 6 mm discs of each scaffold were incubated for up to 24 h in 500 µL of tryptic soy broth,
with the supernatant being collected at 1, 2, 3, 4, 8 and 24 h. At each timepoint the entire 500 µL volume
was collected and replaced with fresh tryptic soy broth. Thus, each time point represents the release of
antimicrobial components between these time points and not the accumulated concentration over time
allowing the duration of antimicrobial effectiveness to be measured. Two assays were used to measure
the antimicrobial duration a growth kinetic assay and an agar well diffusion assay.
To perform the growth kinetic assay, log phase aliquots of either Staph. Aureus (ATCC 29213)
and E. Coli (ATCC 25922) were prepared at a density of 3 × 108 CFU/mL and 100 µL was added to
the well of a 96-well plate. To each bacterial culture, 100 µL of chitosan:ECM scaffold supernatant
was added and mixed thoroughly. The plate was then incubated at 37 ◦C for 18 h with absorbance at
600 nm measured every 20 min using a Spectramax M2 plate reader (Molecular Devices, San Jose, CA,
USA). Bacterial aliquots supplemented with 100 µL tryptic soy broth were used as positive controls
for bacterial growth while tryptic soy broth alone was used as a negative control. All assays were
completed in triplicate. The natural log of the absorbance was calculated and used to plot growth
curves for each experimental group. The slope of the curve over the exponential growth phase was
calculated by linear regression. Where no exponential growth was seen the slope was calculated over
the entire 18 time period and slopes that were not significantly different from zero were assumed to
show no growth while slopes that were significantly different were assumed to show bacterial growth
that did not reach the exponential phase. The lag time was calculated by extrapolating the growth rate
line back to the initial ln OD value at time zero.
The agar well diffusion assay was performed in a similar way to the Kirby–Bauer antibiotic
sensitivity test. In this case, tryptic soy agar plates (100 mm) were prepared by as before with tryptic
soy 100 µL of bacterial suspension (1.5 × 108 CFU/mL) spread across the plate to form a lawn culture.
Using a sterile 6 mm biopsy punch a core of agar was removed from the plate creating a well. The wells
were placed on the plate using a template to ensure 24 mm center to center spacing between each
well. To each well 100 µL of chitosan:ECM scaffold supernatant was added, and the plates were then
cultured overnight at 37 ◦C. Soluble antimicrobial agents diffused into the agar from the well creating
a zone of inhibition which was then measured using calipers. Each combination of scaffold was tested
in triplicate and the average zone of inhibition calculated.
2.5. Measurement of Direct Cytotoxicity
The direct cytotoxicity of the antibiotic-loaded chitosan:ECM scaffolds was tested following the
ISO10993 standard for in vitro cytotoxicity. Human microvascular endothelial cells (HMEC-1, provided
by Dr Francisco Candal, Centers for Disease Control) were used as an established cell line for the assay
which were cultured in standard medium 199 supplemented with 10% fetal bovine serum, 10,000 U
penicillin and 10,000 µg/mL streptomycin (Lonza Biologics, Basel, Switzerland). Scaffold samples for
the assay were prepared by taking a 10 mm diameter sample with a biopsy punch. The samples were
then sterilized by ethylene oxide.
To perform the cytotoxicity assay, HMEC-1 cells were seeded into 35 mm tissue culture dishes at a
density of 1.5 × 105 cells/mL with 1 mL of media per well. The cells were incubated for 24 h to form a
semiconfluent monolayer (60–70% confluence). After 24 h, the culture medium was removed, and
a sterile 10 mm diameter sample of each scaffold was placed in the center of the dish directly over
the cell monolayer. Fresh media was added to the dishes, while ensuring the scaffold remained in
contact with the cells and the cells were incubated for a further 24 h. Untreated cells were included as
a positive control and a certified cytotoxic scaffold control (polyetherurethane (PU) film containing
zinc diethyldithiocarbamate (ZDEC). Japanese Food and Drug Safety Center, Kanagawa, Japan) was
used as a negative control.
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The measurement of neutral red dye uptake was used as a quantitative indication of cell number
and viability based on the work by Borenfreund and Puerner [31]. The scaffold materials were removed
from the dishes and the culture medium was aspirated. The dishes were washed twice with phosphate
buffered saline (PBS) and 1 mL of neutral red medium (1 mL of neutral red stock (0.4 g neutral red in
100 mL type I water) in 79 mL medium 199) was added and the dishes incubated for 3 h. Following
incubation, the dye solution was removed, and the dishes washed twice with PBS. After aspirating the
PBS solution, 1.5 mL of neutral red eluent (1% glacial acetic acid in 50% ethanol) was added and the
dishes were placed on a shaker for 10 min at 100 rpm until the neutral red had been extracted from the
cells and formed a homogenous solution. The solution was then collected and the absorbance @540
nm measured.
2.6. Measurement of Indirect Cytotoxicity
Measurement of indirect cytotoxicity used the same neutral red uptake assay but was performed
in 96 well plates with culture medium extracts from the different scaffold materials. To prepare the
scaffold extracts, 6 mm discs of each scaffold were incubated for up to 24 h in 500 µL of HMEC-1 culture
medium with the supernatant being collected at 1, 2, 3, 4, 8 and 24 h. HMEC-1 cells were resuspended
at a concentration of 1.5 × 105 cells/mL and 100 µL of cell suspension added to the wells of a 96-well
plate and incubated for 24 h at 37 ◦C. After incubation, the culture medium was removed and 100 µL
of each scaffold extract was added to the wells. Untreated cells were included as positive controls.
The plates were then incubated for a further 24 h before the neutral red uptake assay was performed.
The neutral red uptake assay was performed using the same methods as for the direct cytotoxicity
assay but with the volumes reduced to 100 µL for the 96-well plate. Again, absorbance of the neutral
red dye was measured @540 nm.
2.7. Statistical Analysis
All experiments were performed in triplicate and the average values were used for statistical
analysis using analysis of variance (ANOVA), the null hypothesis being that there was no difference
between scaffolds for each test being performed. p ≤ 0.05 was used to identify significant differences.
3. Results
3.1. Scaffold Properties
Representative images of the prepared scaffolds are shown in Figure 1. Endotoxin testing showed
that the prepared chitosan solution contained 5.03 EU/mL. The prepared scaffolds therefore contained
endotoxin proportional to the amount of chitosan used in their fabrication. All the scaffold formulations
that consisted of 100% chitosan or 80:20 and 50:50 chitosan:ECM hydrogel formed a fibrous sponge
like scaffold following lyophilization. The 100% chitosan scaffolds had a firm and dense, but flexible,
structure that was easily cut with a biopsy punch to obtain test samples. The scaffolds incorporating
ECM hydrogel had a softer consistency than 100% chitosan, with the softness increasing with increasing
ECM hydrogel percentage. Obtaining biopsy punch samples for testing was still possible. The scaffolds
that incorporated particulate ECM had a firmer, less flexible structure than those made with ECM
hydrogel or chitosan alone. The 10% ECM scaffolds had a solid inflexible structure that was very easy
to cut and showed very little compression. Addition of the rifampicin and minocycline antibiotics
colored the scaffold either orange or yellow respectively showing that the antibiotic was distributed
homogenously throughout the scaffolds.
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Figure 1. Representative images of the prepared scaffold materials with and without rifampicin
and minocycline antibiotic. Scaffolds were formulated as 100% chitosan, 80/20 and 50/50
chitosan:extracellular matrices (ECM) hydrogel and 1% (w/v) and 10% (w/v) ECM powder in chitosan.
When hydrated, notable differences between the scaffolds were observed. The 100% chitosan
scaffolds retained their structure when hydrated and showed no signs of degradation of dissolution of
the fibrous structure over time. The 80:20 chitosan:ECM scaffolds softened when hydrated becoming
slightly adhesive to any surface upon which they were placed and over time formed a semitranslucent
gel. The 50:50 chitosan:ECM scaffolds quickly formed a translucent gel (approximately 5–10 min)
when hydrated and were more adhesive to a surface that the 100% or 80:20 scaffolds. Over time,
the 50:50 chitosan:ECM scaffolds lost their fibrous structure and after 24 h had turned completely to
hydrogel that could not be picked up with forceps. The 1% ECM and 10% ECM scaffolds both retained
their structure following hydration but swelled in volume over a 24 h period. While the 1% scaffolds
retained their shape after 24 h, the 10% ECM scaffolds began to crumble with increasing hydration
time eventually forming a paste-like putty after 24 h that could still be handled by forceps but could
be spread like a cream when lateral forces were applied. Scaffolds made from 100% ECM hydrogel
were also made, while these scaffolds could be cut with a biopsy punch to obtain test samples, they
had a very soft, friable structure that was easily disrupted and when hydrated these scaffolds rapidly
reverted to hydrogel. These handling characteristics made them unsuitable for testing and they were
excluded from the subsequent experiments.
3.2. Direct Antimicrobial Effects
The chitosan:ECM scaffold formulations showed differences in bacterial response to the antibiotics
used in the study as well as differences in the effectiveness of the antibiotic due to scaffold composition.
Figure 2 shows the zones of inhibition in response to the control discs (5 ug for rifampicin (Figure 2A,C)
and 30 ug for minocycline (Figure 2B,D) for Staph. Aureus and E. Coli, respectively. The clinical isolate
of Staph. Aureus used in the study was found to contain some rifampicin resistant bacteria as shown by
Appl. Sci. 2020, 10, 3446 7 of 21
the small bacterial colonies growing within the zone of inhibition (Figure 2A) but showed no resistance
to the minocycline antibiotic (Figure 2B). The clinical isolate of E. Coli showed some resistance to
the rifampicin antibiotic demonstrated by the reduced size of the zone of inhibition (Figure 2C) but
showed no resistance to the minocycline (Figure 2D). These zones of inhibition were measured and
used to establish a baseline resistance for the two bacterial strains to compare the chitosan:ECM
scaffold combinations.Appl. Sci. 2019, 9, x FOR PEER REVIEW 7 of 21 
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3.2.1. Direct Antimicrobial Effects on Staph. Aureus Bacteria
Notable differences between the scaffolds could be seen (Figure 2E). While in general the scaffolds
without antibiotic showed no antimicrobial effects, the scaffold containing 1% (w/v) ECM powder did
show a detectable antimicrobial effect with a clear zone of inhibition around the scaffold. When loaded
with antibiotic, all the scaffold combinations produced clear zones of inhibition. Compared to the
minocycline control antibiotic sensitivity discs, all the minocycline-loaded chitosan:ECM combinations
produced similar zones of inhibition except for the 1% and 10% ECM where the zones of inhibition
were smaller. In the 10% ECM scaffolds the zone of inhibition was 20% smaller than the control. In
contrast, the rifampicin-loaded ECM scaffolds all showed smaller zones of inhibition compared to
the control discs except for the 80:20 and 50:50 chitosan:ECM combinations. The smallest zones of
inhibition were again in the 10% ECM scaffold group which were 21% smaller than the controls. In
comparison, the 50:50 chitosan:ECM scaffold showed a 6% increase in the zone of inhibition compared
to controls.
3.2.2. Direct Antimicrobial Effects on E. COLI Bacteria
The antimicrobial effects of the chitosan:ECM scaffolds on E. Coli were similar to that with Staph.
Aureus (Figure 2F). With this bacterium, the scaffolds without antibiotic showed no antimicrobial effects.
When loaded with minocycline the chitosan:ECM combinations all showed equal or larger zones
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of inhibition compared to the control except for the 10% ECM scaffold where the zone of inhibition
was 15.9% smaller than the control. While in general the E. Coli bacteria showed resistance to the
rifampicin antibiotic, differences with the chitosan:ECM scaffolds could still be seen. While the 80:20,
50:50 chitosan:ECM and 1% powdered ECM scaffolds showed similar inhibition to the control disc,
the 100% chitosan and 10% powdered ECM scaffolds showed reduced zones of inhibition of 19% and
25%, respectively.
3.3. Duration of Antimicrobial Effects
Duration of the antimicrobial effects of the different chitosan:ECM scaffold formulations was first
tested using the agar well diffusion assay, which showed notable differences in the response of the
two different bacterial strains to the scaffold supernatants (Figure 3). Chitosan:ECM scaffolds without
antibiotic showed no ability to inhibit bacterial growth (data not shown), except for a ~11 mm diameter
zone of inhibition seen in Staph. Aureus bacteria exposed to 1 h supernatant samples of scaffolds 1%
(w/v) ECM powder.
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Zones of inhibition were measure for both Staph. Aureus and E. Coli bacteria.
3.3.1. Duration of Antimicrobial Effect Against Staph. Aureus
When Staph. Aureus was exposed to supernatants from rifampicin-loaded chitosan:ECM scaffolds
or control discs (Figure 3), no differences between scaffolds and control at 1 h were seen. All the
chitosan:ECM formulations showed smaller zones of inhibition at 2 h, except for the 1% (w/v) ECM
scaffolds. Zones of inhibition were smaller for 100% chitosan, 80/20 and 50/50 chitosan:ECM scaffolds at
all subsequent time points with the ability to inhibit bacterial growth diminishing completely between
4 and 8 h. The 1% and 10% (w/v) ECM scaffolds all retained antimicrobial activity up to 24 h. The 1%
(w/v) ECM scaffolds showed no difference to controls except at 8 h. The 10% (w/v) scaffolds showed no
difference to controls except at 24 h where the zone of inhibition was larger than the control.
A similar response pattern was seen when Staph. Aureus was exposed to supernatants from
minocycline-loaded chitosan:ECM scaffolds (Figure 3). The 1 h samples all showed no difference in
the diameter of the zone of inhibition compared to control except for the 1% (w/v) ECM which was
smaller. At 2 h the 80/20, 50/50 chitosan:ECM scaffolds and 1% (w/v) ECM scaffolds had significantly
smaller zones of inhibition compared to control. All the chitosan:ECM formulations had smaller zones
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of inhibition at all subsequent time points up to 24 h. Again, the antimicrobial effect of the 80/20 and
50/50 chitosan:ECM scaffolds was lost between 2 and 3 h and after 4 h in the 100% chitosan:ECM
scaffolds. The 1% (w/v) ECM scaffolds showed some antimicrobial activity up to 24 h but this was not
as pronounced as in the controls. The 10% (w/v) ECM scaffolds had the longest duration antimicrobial
activity and, although the zone of inhibition were smaller than the control, the zone of inhibition
remained a consistent size at each time point and was no different to the control at 24 h suggesting that
the scaffolds containing powdered ECM had a more prolonged the release of the antibiotic from the
scaffold compared to the scaffolds made from chitosan and ECM hydrogel.
3.3.2. Duration of Antimicrobial Effect Against E. Coli
No zones of inhibition were seen when E. Coli were exposed to supernatants from rifampicin-loaded
chitosan:ECM scaffolds or control discs (Figure 3), except for the 1 h supernatant for the control antibiotic
disc. The lack of inhibition was expected given the resistance to rifampicin when the direct antimicrobial
effects were tested.
Minocycline-loaded chitosan:ECM scaffolds showed clear zones of inhibition in all the scaffold
groups at 1 h, but the effect quickly diminished (Figure 3). At all the timepoints tested, the chitosan:ECM
scaffolds were less effective at inhibiting E. Coli growth than the antibiotic control disc supernatants.
In addition, while the control supernatants still had antibiotic concentrations capable of inhibiting E.
Coli growth up to 24 h, in the chitosan:ECM scaffolds inhibition of growth was only seen up to 2 h for
100% chitosan, 50/50 chitosan:ECM and 1% (w/v) ECM scaffolds and up to 3 h in the 10% (w/v) ECM
scaffolds. The 80/20 chitosan:ECM scaffolds were only effective at inhibiting growth for the first 1 h.
3.4. Growth Kinetics Assays
Growth kinetic assays were performed with E. Coli and Staph. Aureus exposed to the same
supernatant samples from the chitosan:ECM scaffold formulations to investigate the duration of
antimicrobial activity further. The growth rate of the bacteria was calculated to determine the
effectiveness of the antibiotic-loaded scaffolds (Figure 4). Scaffold formulations without antibiotics
were tested to determine if the chitosan:ECM formulations had any inherent antimicrobial activity.
When E. Coli were exposed to the supernatants from the scaffolds no antimicrobial effects were seen, all
samples tested resulted in the characteristic bacterial growth curve with a lag time to reach exponential
growth of between 1 and 1.67 h. No significant differences were seen between the different scaffold
materials or between the different supernatant samples (Figure 4A). Interestingly, when the same
supernatant samples were applied to Staph. Aureus bacteria some antimicrobial activity was seen
(Figure 4B). In the 1-h supernatant samples the 100% chitosan, 80/20 chitosan:ECM and 1% (w/v) ECM
scaffolds all reduced the growth rate of the bacteria. Bacterial growth was not completely inhibited, but
the growth rate was reduced and never reached the exponential phase over the 18 h of the test. These
results suggest that these formulations may have a bacteriostatic effect inhibiting growth but not killing
the bacteria. The 50/50 chitosan:ECM and 10% (w/v) ECM scaffolds at this timepoint did not inhibit
bacterial growth; however, the 2-h supernatant samples from all the scaffold formulations reduced
bacterial growth and prevented exponential growth phase. At three hours the 50/50 chitosan:ECM
and 1% and 10% (w/v) ECM scaffolds continued to show reduced bacterial growth, however the 1%
chitosan and 80/20 chitosan:ECM supernatants no longer inhibited bacterial growth. Moreover, the
100% chitosan and 80/20 chitosan:ECM supernatant samples between 1 and 4 h showed a gradual
increase in bacterial growth suggesting that any antimicrobial molecules release by the scaffolds had
completed eluted by 4 h. All the scaffold formulations had lost their antimicrobial effect by 4 h with
no differences in bacterial growth being seen between the different scaffolds or between different
supernatant samples between hours 4 and 24.
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Figure 4. Graphs showing the calculated growth rate of E. Coli (A,C,E) and Staph. Aureus (B,D,F)
bacteria exposed to different scaffold formulation supernatants. (A,B) growth rate of E. Coli (A) and
Staph. Aureus bacteria when exposed to supernatant samples from scaffold formulations without
antibiotics; (C,D) growth rate of E. Coli (C) and Staph. Aureus (D) when exposed to supernatant samples
of rifampicin-loaded scaffold formulations; (E,F) growth rate of E. Coli (E) and Staph. Aureus (F) when
exposed to supernatant samples of minocycline-loaded scaffold formulations.
Supernatants from scaffolds containing antibiotic showed similar result to the agar diffusion assay,
but the growth curves allowed for a more detailed analysis of the bacterial growth. When E. Coli were
exposed to supernatants from rifampicin-loaded chitosan:ECM scaffolds bacterial growth was seen
in all supernatant samples taken between 2- and 24-h indicative of the resistance E. Coli had to the
rifampicin antibiotic (Figure 4C). However, supernatant samples taken after 1 h did show inhibition of
growth. While the 1 h supernatant samples from 100% chitosan and 10% (w/v) ECM scaffolds showed
bacterial growth, in the 10% (w/v) ECM group this growth rate never reach the exponential phase while
in the 100% chitosan group the exponential phase of growth was delayed with a lag time of 6.63 h
compared to lag time of 1.30 h for the same scaffold without antibiotic. No bacterial growth was seen
in the 80/20 or 50/50 chitosan:ECM groups or in the 1% (w/v) ECM group.
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Supernatants from minocycline-loaded chitosan:ECM scaffolds showed clear differences in the
effectiveness of the scaffold formulations (Figure 4E). The supernatant samples taken at 1 h and 2 h
from all the scaffold formulations completely inhibited bacterial growth and there were no differences
between the different scaffold formulations. However, the supernatant samples taken at 3 h for
the 80/20 and 50/50 chitosan:ECM formulations did not inhibit bacterial growth, and both showed
exponential growth. Bacterial growth was also seen in the 1% (w/v) ECM supernatant group but this
was a continuous growth that did not reach the exponential phase suggesting this scaffold formulation
still had a bacteriostatic effect even though its bactericidal effects had been lost. The supernatants from
the 10% (w/v) ECM group completely inhibited bacterial growth at 3 h and no growth was seen at
any other timepoint all the way to 24 h indicating that this scaffold formulation continued to have a
prolonged bactericidal effect and a slower release of the antibiotic than the other scaffold formulations.
None of the other scaffold formulations were able to inhibit bacterial growth after 3 h, while there were
differences in the growth rates between scaffolds all the growth curves followed the typical bacterial
growth curve.
Staph. Aureus exposed to supernatants from rifampicin-loaded chitosan:ECM scaffolds showed
growth that was completely inhibited by supernatant samples from all the scaffolds taken at 1 and 2
h (Figure 4D). Supernatant samples taken from the 80/20 chitosan:ECM and 10% (w/v) ECM groups
at 3 h were still able to completely inhibit bacterial growth. The 100% chitosan, 50/50 chitosan:ECM
and 1% (w/v) ECM groups all showed bacterial growth that reached the exponential phase. However,
the lag times for each scaffold were extended to 13.26, 9.25 and 11.77 h for each scaffold, respectively,
compared to a normal lag time of between 0.56 and 1.03 h for the equivalent scaffolds without antibiotic.
Interestingly, while the supernatant samples from 100% chitosan at 3 h resulted in exponential
bacterial growth, samples from the same scaffold at 4 h and 8 h did not reach the exponential phase.
Supernatants from the 1% (w/v) and 10% (w/v) ECM groups at 4, 8 and 24 h completely inhibited
bacterial growth. These results suggest that in these scaffolds there may be a prolonged release of
the antibiotic, or the release of other antimicrobial molecules from the scaffold as the scaffold begins
to degrade. Supernatants from the 80/20 chitosan:ECM group inhibited growth at 4 h but did not
inhibit growth at 8 or 24 h although the lag time before reaching exponential growth was extended
to 3.60 and 4.20 h at 8 and 24 h, respectively. Similarly, the 50/50 chitosan:ECM scaffolds did not
inhibit bacterial growth at 4, 8 or 24 h, but the lag time to reach exponential phase was extended
to 10.60, 3.70 and 4.56 h at each timepoint, respectively. This extension of the lag phase is probably
indicative of the fact that a population of the Staph. Aureus clinical isolate was resistant to rifampicin,
as demonstrated on the bacterial growth plates and this population of bacteria was able to proliferate
while the rifampicin-sensitive population was killed.
Growth of Staph. Aureus was completely inhibited by supernatants from minocycline-loaded
chitosan:ECM scaffolds taken at 1 and 2 h (Figure 4F). Supernatant samples taken at 3 h from all
the scaffolds except the 80/20 chitosan:ECM group were able to completely inhibit growth. The
80/20 chitosan:ECM group did show bacterial growth, but this failed to reach the exponential
phase. Exponential bacterial growth was subsequently seen with supernatant samples from the 80/20
chitosan:ECM group at all the remaining time points except 24 h where the growth rate did not become
exponential. Bacterial growth continued to be inhibited by the minocycline-loaded 100% chitosan
group after 4 h while the antibiotic-loaded 50/50 chitosan:ECM, 1% and 10% (w/v) ECM groups all
showed some bacterial growth that did not reach the exponential phase. Supernatant samples taken at
8 h, apart for the previously discussed 80/20 chitosan:ECM group, all showed bacterial growth that was
significant but did not become exponential except for the minocycline-loaded 10% (w/v) ECM which
completely inhibited bacterial growth. This inhibition of bacterial growth in the antibiotic-loaded 10%
(w/v) ECM scaffold group continued at 24 h while all the other scaffold groups showed bacterial growth
that did not reach the exponential phase. This again suggests that the 10% (w/v) ECM formulation
prolonged the release of the antibiotic from the material while the biphasic growth seen in the other
Appl. Sci. 2020, 10, 3446 12 of 21
scaffold formulations may suggest that other antimicrobial molecules, that Staph. Aureus are more
sensitive to than E. Coli, are being released as the ECM scaffolds degrade.
3.5. Direct Cytotoxicity Testing
Direct cytotoxicity testing was performed to determine whether the scaffold materials were
cytotoxic to human microvascular endothelial cells. Antibiotic-loaded and nonantibiotic-loaded
scaffolds were tested and compared to the negative and positive controls. Scaffolds were considered
to have a cytotoxic effect if ANOVA showed no difference to the negative control and a significant
difference to the positive control. The results of the neutral red uptake are shown in Figure 5.Appl. Sci. 2019, 9, x FOR PEER REVIEW 12 of 21 
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directly to the different scaffold formulations with and without antibiotics. Red li i
aver g neutral red uptake of c lls expos d to ISO standard cytotoxic c ntrol, while the blue line shows
the level of n utral red up ake in cells grown with ut scaffold exposure.
All the scaffold for ulations without antibiotic showed no difference in neutral red uptake
compar d to the positive control except for the 10% (w/v) ECM scaffolds. Significant differences were
seen i all the scaffold formulations w en compared to the negative control, except for the 1% and 10%
(w/v) ECM scaffolds that showed no differences. These results indicate that th 10% (w/v) ECM scaffold
was having a cytotoxic effect on the human microvascular endothelial cells while the 1% (w/v) ECM
may be reduci g cell viability.
Assessment of minocycline-loaded scaffolds showed that all the scaffold formulations were
different to the negative control except for the 10% (w/v) ECM and, compared to the positive control,
only the 10% (w/v) ECM scaffold showed a difference. This result would again indicate that the
10% (w/v) scaffold formulation had a direct ytotoxic effect the c lls. Interest ngly, assessment of
rifampicin-loaded scaffolds showed that cells exposed to the 10% (w/v) ECM again had the lowest
uptake of neutral red. However, none of the f rmulations were different to the positive, no scaffold
control, and all the formulation were different to the negative control.
3.6. Indirect Cytotoxicity Testing
The potential cytotoxic effects of the scaffold formulations were further elucidated using indirect
cytotoxicity testing. Using culture media supernatants taken from scaffold samples after 1, 2, 3, 4, 8
and 24 h would determine whether components eluted from the scaffolds had a cytotoxic effect. These
supernatant samples represented the total eluted molecules after each time point. The neutral red
uptake results for the scaffolds alone and for each antibiotic-loaded group are shown in Figure 6.
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Figure 6. Graph showing the neutral red uptake by human microvascular endothelial cells exposed to
supernatant samples from scaffold formulations with and without antibiotics. Supernatant samples
were collected at 1, 2, 3, 4, 8 and 24 h. (A) Neutral red uptake of cells exposed to supernatant samples
from scaffold formulations without antibiotic; (B) neutral red uptake of cells exposed to supernatant
samples from scaffold formulations loaded with minocycline; (C) neutral red uptake of cells exposed to
supernatant samples from scaffold formulations loaded with rifampicin. Blue line shows neutral red
uptake of cells cultured in culture media alone (no scaffold control).
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Supernatant samples from all the scaffold formulations, regardless of the presence or absence
of antibiotic, showed reduced neutral red uptake compared to the no scaffold control at all the time
points tested, only the 80/20 chitosan:ECM supernatant at 4 h and the rifampicin-loaded 100% chitosan
scaffold supernatant at 2 h showed similar uptake to the positive control. These results suggest that
molecules eluted from these scaffolds did have the ability to inhibit cells growth. Comparison with the
negative control would subsequently identify those samples that had a measurable cytotoxic effect on
the cells.
Supernatant samples from the scaffolds without antibiotic (Figure 6A) showed that neutral red
uptake from cells exposed to the eluted products from the 100% chitosan scaffolds was no different
to the negative control at any time point, indicative of a cytotoxic effect. Cytotoxic effects were also
seen with the other scaffold formulations, but the effect varied depending of the time point sampled.
For example, the eluted molecules in the supernatant samples from 1% and 10% (w/v) ECM scaffolds
did not become cytotoxic to the microvascular endothelial cells until 4 h, while the 80/20 and 50/50
chitosan:ECM scaffolds were more variable with some time points showing a difference to the negative
control and others showing no difference. The results suggest that while cell growth was inhibited,
the cytotoxic effects may be borderline and affected by the variability of the neutral red uptake by the
negative control cells.
Supernatant samples from the scaffolds loaded with minocycline (Figure 6B) again showed that
neutral red uptake from cells exposed to the eluted products from the 100% chitosan scaffolds was
no different to the negative control at any time point except at 24 h. In addition, eluted molecules
from the minocycline-loaded 1% (w/v) ECM again showed no cytotoxic effects until hour 4. The
minocycline-loaded 50/50 chitosan:ECM scaffolds and the 10% (w/v) ECM scaffolds showed reduced
cell growth but no cytotoxicity at hour 1, whereas the supernatants had a cytotoxic effect at all other
time points. In contrast, the 80/20 chitosan:ECM scaffolds were more variable and alternated between
cytotoxic at hours 1, 4, 8 and 24 and not cytotoxic at hours 2 and 3, although these still had reduced
neutral red uptake compared to the positive samples.
Supernatant samples from scaffolds loaded with rifampicin (Figure 6C) showed a similar pattern
to the minocycline-loaded scaffold results. The supernatants from the 50/50 chitosan:ECM scaffolds
were all classified as cytotoxic at all time points, while the 100% chitosan samples showed cytotoxicity
at every time point except 2 h. The other scaffold formulations were more variable. The 10% (w/v)
scaffold supernatants showed reduced neutral red uptake but not cytotoxicity at hours 1 and 2 but
were cytotoxic at all subsequent time points. The 1% (w/v) scaffold supernatants alternated between
having reduced neutral red uptake but not true cytotoxicity at hours 1, 3 and 24 to being cytotoxic at
hours 2, 4 and 8. Similarly, the 80/20 chitosan:ECM scaffolds at 2, 3 and 24 h had reduced neutral red
uptake but only the supernatants from 1, 4, and 8 h showed no difference to the negative controls.
Overall, the results of the cytotoxicity testing indicated that all the scaffold formulations could
reduce neutral red uptake by the microvascular endothelial cells directly and could reduce uptake to a
level that would be classified as cytotoxic. However, it did not appear that the elution of the antibiotic
from the scaffold into the culture medium had a significant indirect cytotoxic effect since no differences
between the antibiotic-loaded scaffolds and the nonantibiotic-loaded scaffolds were seen.
4. Discussion
The textbook description of wound healing presents the process as a series of overlapping stages
including hemostasis, re-epithelialization, inflammation and the formation of granulation tissue and
finally remodeling. However, the healing of traumatic injuries is never this simple and the process
of wound healing can be delayed by factors such as excessive bleeding, bacterial and foreign object
contamination. Wound dressings aim to promote hemostasis, and ideally possess antimicrobial
properties and factors to promote wound healing. The development of a multifunctional wound
dressing has been a goal in trauma care for several years, particularly for tactical combat casualty care
(TCCC) in the armed forces. Uncontrolled hemorrhage remains the leading cause of trauma deaths in
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both the combat and civilian settings accounting for 60% of preventable combat death [30,31]. Moreover,
there is a growing incidence of bacterial wound infection, particularly in combat injuries [32–34], that
is stimulating the development of new wound treatments. The dressing developed in the present
study was built on a platform that utilizes two different extracellular matrices (ECM): ECM from
decellularized mammalian tissue and ECM (chitosan) from crustaceans. These were chosen since both
types of ECM have well established clinical benefits in promoting wound healing and controlling
hemostasis. This hybrid ECM platform was augmented with the addition of antibiotics, aimed to boost
bactericidal activity at the wound site.
The use of chitosan as a wound dressing is well established with a number of groups using it as a
wound dressing on its own or in combination with other polymers, proteins or proteoglycans [35–44].
Similarly, ECM from decellularized mammalian tissue is already used in the manufacture of several
wound dressing products [45–47]. While these decellularized tissue scaffolds are primarily used to
promote rapid wound healing and constructive tissue remodeling, previous studies have shown
that the degradation products of these materials have direct antimicrobial effects [48] and indirect
antimicrobial effects through regulation of the inflammatory response [49,50]. Chitosan has also been
shown to have antimicrobial properties, although, this may be dependent on the preparation method
and pH with poor solubility of chitosan and the loss of the cationic charge in neutral and alkaline
environments being two of the major obstacles to its antimicrobial activity [25,26,51]. Since the scaffolds
used in the present study were prepared in a neutral environment and used either pepsin-digested
mammalian ECM or comminuted powder, it was of interest to see if these materials without antibiotic
augmentation possessed any antimicrobial activity. Interestingly, under certain circumstances, the
scaffolds alone did have antimicrobial activity against Staph. Aureus bacteria, but not E. Coli. Looking
at the zone of inhibition around the different scaffold formulations all the scaffolds, the scaffolds
made from 100% chitosan or the 80/20 and 50/50 chitosan ECM hydrogel mix showed a small zone
of inhibition around the scaffold that was only 1 mm larger than the scaffold disc at most. Only the
1% (w/v) scaffolds produced a clear, consistent zone of inhibition that was over 4 mm larger than the
scaffold discs. Similarly, when the growth rates of Staph. Aureus were compared after exposure to the
scaffold supernatants, some degree of bacteriostatic effect was seen with supernatant samples from
incubations up to 3 h where all the scaffold formulations were able to reduce, but not completely
inhibit, bacterial growth.
The inclusion of antibiotics into the scaffold formulations had an obvious effect on the antimicrobial
properties of the scaffolds. The two antibiotics, minocycline and rifampicin, were chosen because
these were antibiotics already approved to the use in topical wound dressings and the dosage was
matched to that used in antibiotic sensitivity discs to allow easy comparison to a representative
control. Consequently, this proof of principle experiment did not attempt to optimize the antibiotic
concentration and it is possible that some of the results of the antimicrobial and cytotoxicity tests
would have been different had an optimal dose been used. The clinical isolates of bacteria that were
used in this study also had different sensitivities to the antibiotic. Both E. Coli and Staph. Aureus
showed resistance to the rifampicin antibiotic, but in the case of Staph. Aureus, it was only a specific
subpopulation of bacteria that were resistant. The presence of these resistant strains explains the
growth rate results seen with the scaffold supernatants. In these studies, the antibiotic was effective
at killing the rifampicin-sensitive bacteria but allowed the resistant strain to survive and eventually
proliferate at an exponential rate resulting in the long lag times of 10–13 h that were seen. Other
groups have shown that chitosan scaffolds can be loaded with other antibiotics with similar results
to the present study. Fazli and Shariatini prepared chitosan–polyethylene oxide scaffolds that were
loaded with cefazolin and cefazolin-loaded silica nanoparticles [52]. They showed that the antibiotic
was released from the scaffolds easily and that they were 100% effective against Staph. Aureus and
E. Coli in vitro. Mi et al. used a chitosan scaffold as a delivery vehicle for silver sulfadiazine which
showed similar release profiles to the scaffolds in the present study by had antimicrobial effectiveness
up to 1 week and was successful at inhibiting Pseudomonas Aeruginosa and Staph. Aureus infection in
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wounds in vivo [53]. Tennent et al. used chitosan sponges to deliver a combination of vancomycin and
tobramycin, testing the effectiveness using bioluminescent strains Staph. Aureus and P. Aeruginosa in a
large animal model. While the wound healing properties of the scaffolds were not investigated, they
showed that the antibiotic-loaded scaffolds effectively reduced, but did not completely eliminate, the
bacterial infection, while unloaded scaffolds allowed the bacteria to grow and proliferate [54].
Interestingly, the incorporation of mammalian ECM, whether in hydrogel form or particulates,
appeared to alter the effectiveness and release rate of the antibiotics. 1% (w/v) and 10% (w/v) ECM
scaffolds had a sustained release of minocycline and rifampicin that was effective at inhibiting bacterial
growth for up to 24 h, while the 100% chitosan, 80/20, and 50/50 chitosan:ECM scaffolds released the
antibiotic faster and lost their effectiveness typically after around 3 h. Moreover, when looking at the
effect of minocycline-loaded scaffolds on E. Coli, while the antibiotic sensitivity discs inhibited bacterial
growth of up to 24 h, all the scaffold formulations lost their original effectiveness after approximately
2–3 h suggesting that the effectiveness of the antibiotic was being altered by the material properties
of the scaffolds. Antibiotic release by the scaffolds was expected to be by passive diffusion and so
prolonged release of the antibiotic promoted by the presence of ECM is not thought to be the result
of direct protein interaction between the ECM and the antibiotics. However, this interaction was not
investigated. The more likely explanation is that the presence of ECM increases the ability of the
scaffolds to retain water since the hydrated ECM is approximately 90% water, resulting in slower
diffusion of the antibiotic out of the scaffold material. Modulating the release profile of the antibiotics
could be modified further in a number of ways. Chemical cross-linking of the scaffold materials would
prevent degradation of the material potentially prolonging antibiotic release. However, cross-linking
would reduce the constructive remodeling properties of the ECM scaffolds [55,56]. An alternative
approach would be to encapsulate the antibiotic in some form of microsphere. Chitosan microspheres
have been developed to provide a variety of controlled-release molecules including antimicrobial
chemicals [57–60]. These microspheres could easily be incorporated into the current scaffold design to
provide prolonged antibiotic release, or even incorporation of a secondary antibiotic or wound healing
factor to further promote wound healing.
The antimicrobial effectiveness of the scaffolds is of little consequence if the scaffold formulations
prove to be cytotoxic. Two tests for cytotoxicity were performed flowing ISO standards to test the
direct and indirect cytotoxic properties of the scaffolds. Chitosan and mammalian ECM were not
expected to be cytotoxic, although some studies have shown that these materials, or their structural
composition, can affect cell growth, proliferation and cell infiltration. Under certain conditions and
preparation methods, chitosan has been shown to support poor cell growth with cells remaining
rounded and clumping together [61,62]. While mammalian ECM contains components that promote
cell attachment, dense ECM scaffold materials such as multilaminated scaffolds, can slow cellular
growth and inhibit cellular infiltration [56,63,64]. The neutral red uptake assay is designed to test
cytotoxicity independently of the ability of the scaffolds to support cell growth as the scaffold materials
are applied to the cells, rather than vice versa as is more commonly done. Interestingly, the 1% (w/v)
and 10% (w/v) ECM formulations showed reduced cell viability with or without antibiotic loading, with
the 10% (w/v) ECM scaffold meeting the criteria for being classified cytotoxic. Since ECM is not known
to be cytotoxic, this was an unexpected result and one that requires further analysis. Endotoxin testing
of the chitosan component of the scaffolds showed that the starting solution (100% chitosan) contained
approximately 5 EU/mL (approximately 0.5 mg/mL). Since endotoxin activity depends on a variety of
factors such as polysaccharide chain length, solubility and source, the possibility that endotoxin is the
cause of the cytotoxicity cannot be ruled out. Studies of the effects of endotoxin generally use much
higher endotoxin levels than those found in the present study, typically using levels in the microgram
rather than nanogram range. Nalbantsoy et al. showed that 100 ug/mL were capable of altering the
morphology and could reduce the proliferation rate of hybridoma cells by 62% [65]. Unger et al. have
compared the LAL endotoxin assay to a cell-based assay using microvascular endothelial cells. While
they did not specifically look at viability of the cells, they did show that microvascular endothelial cells
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were particularly sensitive to endotoxin, resulting in significant changes in e-selectin expression [66].
The neutral red uptake assay does have a high sensitivity that may lead to false positive results and the
experiment must be carefully controlled using known standards for cytotoxicity. It is a possibility that
since this scaffold formulation was shown to swell and lose integrity when hydrated, cell attachment to
the scaffold or sloughing of the cell monolayer during scaffold removal may have occurred, reducing
the cell density and therefore reducing neutral red uptake relative to the other materials. Specific cell
attachment assays would help to understand this result and will be performed in the future. While
the direct cytotoxicity assays showed that only the two scaffold formulations containing particulate
ECM reduced neutral red uptake, the indirect cytotoxicity assays showed that neutral red uptake was
reduced by all the supernatant samples of all the scaffold formulations. The presence of the antibiotics
did not significantly change the cellular response to the scaffold supernatants suggesting that the
antibiotics themselves were not cytotoxic but rather something in either the chitosan or ECM that was
having the effect. Again, this response to the ECM material was a surprising result since both these
materials are considered biocompatible in several applications and are approved for use in wound
dressings without adverse reactions [13,47,67,68]. Studies looking at endotoxin burden of ECM-based
scaffolds have shown that while endotoxin definitely influences the short-term host response to these
materials, the long-term constructive remodeling effects were unchanged [69]. It is possible that the
sensitivity of the neutral red assay was influenced by the endotoxin content of the scaffolds, but it
remains to be seen if this would alter the long-term success of the scaffold materials in vivo. It is also
possible that serum proteins within the media being used to prepare the supernatants could have
adsorbed or bound to proteins within the scaffold [70], reducing their availability to the cells.
5. Conclusions
In summary, the present study has shown that hybrid dressing materials comprising chitosan
and mammalian ECM can be produced and form stable, useable dressing materials. The use of ECM
hydrogel versus particulate ECM results in clear differences in the scaffold handling properties, scaffold
integrity over time and in the effectiveness and release rate of loaded antibiotics. Moreover, antibiotics
directly mixed with the chitosan:ECM mixture are easily released from the scaffold and remain effective
for at least 2 h but can be extended up to 24 h by modifying the scaffold composition. Variable results
with cytotoxicity testing show that further work is required to optimize the scaffold formulations and
direct cell culture of the cells on the scaffolds is necessary to validate the cytotoxicity results before
preclinical testing. However, these early proof of principle experiments suggest that these scaffolds
may have potential as viable bioactive wound dressings.
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